Pharmaceutical Industry Archives – Treatment Action Group

New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use

December 15, 2025
Dorrit Walsh

Behind many lifesaving vaccines is a fragile supply chain that few people ever see. This new TAG report examines how weaknesses in the production and supply of key vaccine adjuvants (an ingredient that enhances the immune response) can create bottlenecks that threaten global access to vaccines, underscoring the importance of greater market transparency, security, and competitiveness among governments, funders, and pharmaceutical companies.

TAG Calls on Danaher to Drop the Prices of GeneXpert Tests and Make the Cost Audit Public

June 26, 2024
Dorrit Walsh

Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

June 20, 2024
Dorrit Walsh

Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.

TAG Condemns GSK Actions Surrounding Potential TB Vaccine Revealed by Bombshell ProPublica Report

October 6, 2023
Dorrit Walsh

TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.

TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline

October 2, 2023
Dorrit Walsh

TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.

Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply

August 1, 2023
Dorrit Walsh

TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.

TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands

July 13, 2023
Dorrit Walsh

After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...

Open Letter: Urgent Action Necessary for Equitable Access to Bedaquiline in All Countries with High Burdens of TB, MDR-TB, and TB/HIV

July 11, 2023
Dorrit Walsh

TAG and 82 other organizations and 106 individuals representing TB-affected communities and civil society sent an open letter to Johnson & Johnson calling on the company...

The 1/4/6×24 Campaign Coalition Welcomes India’s Rejection of Johnson & Johnson’s Patent Evergreening Tactic

March 28, 2023
Dorrit Walsh

The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.

TAG Applauds Price Reduction of Molbio’s Truenat Diagnostics for Tuberculosis

March 17, 2023
Dorrit Walsh

Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.